NCT04703075View on ClinicalTrials.gov

Ultra Curto (Ultra Short) TB Prevention Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

531

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions
Tuberculosis
Interventions
DRUG

Rifapentine 600 mg and INH 300 mg

Participants will receive Rifapentine 600 mg and INH 300 mg

DRUG

Rifapentine 900 mg and INH 900 mg

Participants will receive Rifapentine 900 mg and INH 900mg

Trial Locations (2)

69040-000

Fundacao de Medicina Tropical Doutor Heitor, Manaus

22450-221

NAPDOT, Rio de Janeiro

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Sanofi

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT04703075 - Ultra Curto (Ultra Short) TB Prevention Therapy | Biotech Hunter | Biotech Hunter